医学临床研究
  2025年4月8日 星期二           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2019, Vol. 36 Issue (7): 1249-1251    DOI: 10.3969/j.issn.1671-7171.2019.07.001
  论著 本期目录 | 过刊浏览 | 高级检索 |
子宫内膜癌错配修复蛋白表达与临床病理特征和预后相关性分析
闵慜, 吴霞**
上海交通大学医学院附属仁济医院妇产科,上海 200127
Analysis of Correlation between Mismatch Repair Protein Expression and Clinicopathological Features and Prognosis in Endometrial Cancer
MIN Min, WU Xia
Shanghai Key Laboratory of Gynecologic Oncology,Renji Hospital Affiliated to Medical College of Shanghai Jiao Tong University, Shanghai 200127, China
全文: PDF (0 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨错配修复(MMR)蛋白(MLH1、PMS2、MSH2和MSH6)表达与子宫内膜癌临床病理特征和预后相关性分析。【方法】收集2010年1月至2016年6月在上海交通大学医学院附属仁济医院诊治的143例子宫内膜癌患者组织标本,免疫组化检测子宫内膜癌组织中MMR蛋白(MLH1,PMS2,MSH2,MSH6)表达情况,分析MMR蛋白的表达与患者临床病理特征及术后2年疾病复发率的相关性。【结果】143例子宫内膜癌患者中, MLH1、PMS2、MSH2和MSH6中至少一个指标表达缺失39例,表达缺失率为27.3%(39/143)。MMR蛋白表达缺失与肿瘤家族史、子宫内膜样腺癌组织学分级及脉管侵犯显著相关性(P<0.05),与年龄、组织学类型、FIGO分期、肌层的浸润深度及淋巴结转移无明显相关性(P>0.05)。MMR蛋白表达缺失子宫内膜癌患者术后2年的疾病复发率17.9%,与MMR蛋白表达正常患者的19.2%比较差异无统计学意义(P>0.05)。【结论】子宫内膜癌中MMR蛋白表达缺失与肿瘤家族史、子宫内膜样腺癌分级高、脉管侵犯呈显著相关;MMR蛋白表达正常与MMR蛋白表达缺陷患者2年的疾病复发率比较差异无显著性,远期预后有待进一步随访研究。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
闵慜
吴霞
Abstract【Objective】To investigate the correlation between the expression of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2 and MSH6) and the clinicopathological features and prognosis of endometrial cancer.【Methods】The expression of MMR protein (MLH1, PMS2, MSH2, MSH6) in endometrial cancer tissues was analyzed by immunohistochemistry. The correlation between the expression of MMR protein and the clinicopathological characteristics of patients and the recurrence rate of disease 2 years after operation were compared .【Results】Among 143 cases of endometrial cancer, 39 cases (27.3%) had at least one expression deletion in MLH1, PMS2, MSH2 and MSH6. The expression of MMR protein was significantly correlated with family history, histological grade and vascular invasion of endometrioid adenocarcinoma (P<0.05), but not with age, histological type, FIGO stage, depth of myometrial invasion and lymph node metastasis (P>0.05).The recurrence rate of endometrial cancer patients with loss of MMR protein expression was 17.9% in 2 years after operation, which was not significantly different from that of patients with normal MMR protein expression (19.2%) (P>0.05).【Conclusion】The loss of MMR protein expression in endometrial cancer is significantly correlated with family history, high grade of endometrioid adenocarcinoma and vascular invasion. There is no significant difference in recurrence rate between patients with normal MMR protein expression and patients with deficient MMR protein expression in 2 years. The long-term prognosis needs further follow-up study.
收稿日期: 2018-11-06     
PACS:  R737.33  
基金资助:国家自然科学基金面上项目(编号:81472843)
通讯作者: **,E-mail: wuxia1225@aliyun.com   
引用本文:   
闵慜, 吴霞. 子宫内膜癌错配修复蛋白表达与临床病理特征和预后相关性分析[J]. 医学临床研究, 2019, 36(7): 1249-1251.
MIN Min, WU Xia. Analysis of Correlation between Mismatch Repair Protein Expression and Clinicopathological Features and Prognosis in Endometrial Cancer. JOURNAL OF CLINICAL RESEARCH, 2019, 36(7): 1249-1251.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2019.07.001     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2019/V36/I7/1249
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn